News

Apexian Pharmaceuticals to participate in the National Cancer Institute’s SBIR Investor Initiatives program

Indianapolis-based Apexian Pharmaceuticals, a clinical-stage biotech company developing novel compounds to treat cancer by leveraging intellectual property discovered at the Indiana University School of Medicine has been selected to participate in the National Cancer Institute’s SBIR Investor Initiatives program. As part of the program, Dr. Richard Messmann — Apexian’s chief medical officer — will present at the BioNetwork Partnering Summit taking place Oct. 23-25 in...

National Cancer Institute selects Apexian Pharmaceuticals to participate in the Small Business Innovation Research (SBIR) Initiative program

Indianapolis, IN – September 27, 2017 –Apexian Pharmaceuticals is pleased to announce that the National Cancer Institute (NCI) has selected the company to participate in its highly competitive Small Business Innovation Research (SBIR) Investor Initiatives program, that encourages domestic small businesses to engage in Research and Development (R&D) that has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore...